Evidence map›Paper›PMID 42415656›Full record

ArticleChembiochem : a European journal of chemical biology2026

Structure and Activity of Class II Lanthipeptides From a Thermophilic Bacterium.

Enleyona Weir, Lingyang Zhu, Wilfred A van der Donk

Abstract read
In one paragraph

Article in Chembiochem : a European journal of chemical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Enleyona WeirDepartment of Chemistry and Howard Hughes Medical Institute, University of Illinois at Urbana-Champaign, Urbana, IL, USA.
Lingyang ZhuSchool of Chemical Sciences NMR Laboratory, University of Illinois at Urbana-Champaign, Urbana, IL, USA.
Wilfred A van der DonkDepartment of Chemistry and Howard Hughes Medical Institute, University of Illinois at Urbana-Champaign, Urbana, IL, USA.ORCID https://orcid.org/0000-0002-5467-7071

Funding

A Scalable Platform to Discover Antimicrobials of Ribosomal OriginR01AI144967 · NIAID · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI Douglas Alan Mitchell, WILFRED A. VAN DER DONK · 2019 to 2026
$6.0M
NIH HHS R01 AI144967Roy J. Carver Charitable Trust 22-5622
6 · The paper itself

Abstract

Lanthipeptides represent a large group of ribosomally synthesized and post-translationally modified peptides (RiPPs). They offer promising avenues for discovering new antibacterial and antifungal agents. Here, we identify and structurally analyze the product of the tla BGC, which encodes a class II lanthipeptide in the thermophilic bacterium Thermoactinomyces sp. DSM 45891. Coexpression of the lanthipeptide synthetase TlaM with its substrates in Escherichia coli resulted in modification of the two precursor peptides TlaA1 and TlaA2, which share 58% sequence identity. TlaA1 was dehydrated up to seven times, with the major products having undergone five and six dehydrations, whereas TlaA2 was dehydrated seven times. In both peptides, four thioether rings were formed with two overlapping DL-(methyl)lanthionine rings at the C-terminus. Both peptides also contain two nonoverlapping DL-methyllanthionines near the N-terminus and in the center of the peptide. These peptides deviate from the general rule of stereoselective LL-(methyl)lanthionine formation from a Dhx-Dhx-Xxx-Xxx-Cys motif (Dhx = dehydroalanine or dehydrobutyrine). AspN-cleaved TlaM-modified TlaA1 displayed antimicrobial activity against a subset of bacteria, including Gram-negative ESKAPE pathogens. We named the lantibiotic thermolanthin.

Indexed as

Anti-Bacterial AgentsBacteriocinsPeptidesThermoactinomycesAlanineAmino Acid SequenceEscherichia coliProtein Processing, Post-TranslationalSulfidesAlanineAnti-Bacterial AgentsBacteriocinslanthioninePeptidesSulfidesbiosynthesislanthioninelantibioticMarfey's analysisribosomally synthesized and post‐translationally modified peptide (RiPP)

Identifiers

PMID42415656
PMCPMC13343206

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.